Amylin Pharmaceuticals Inc detailed Quarterly and Annual Revenue year on year Growth Analysis, results, statistics, averages, rankings and trends CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. These are the largest companies by revenue. Comment. Its loss is twice that.

Amylin Pharmaceuticals General Information Description. Amylin Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2010. Amylin Pharmaceuticals is a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs. Research and development expenses increased to $40.9 million from $25.8 million, while SG&A rose to $14.9 million from $6.2 million. Amylin was discovered by researchers at Oxford University earlier that year. Action Alerts PLUS is a registered trademark of TheStreet, Inc. Develops a line of diagnostic and therapeutic products for diabetics. Analysts polled by Thomson First Call were expecting a loss of 40 cents a share on revenue of $16.04 million. Market Share of Amylin Pharmaceuticals's Largest Competitors A competitive analysis shows these companies are in the same general field as Amylin Pharmaceuticals, even though they may not compete head-to-head. Developer of drugs for the treatment of diabetes, obesity and other diseases.

Amylin completed its IPO in 1992. How many Employees Amylin Pharmaceuticals Inc has? The increases reflected the cost of a larger workforce, increased medical education and other prelaunch expenses for Symlin, an anti-diabetes drug. In the period, Amylin Pharmaceuticals Inc's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago. Working towards a cure for diabetes by challenging science, changing lives. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. © 2020 TheStreet, Inc. All rights reserved. Companies with similar Revenue rise for the quarter ending Jun 30 2012 within Healthcare Sector, Revenue for the quarter ending Jun 30 2012. Major Pharmaceutical Preparations Industry, Amylin Pharmaceuticals Inc's Income per Employee, Employees in Major Pharmaceutical Preparations, Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics, Healthcare Sector Revenue per Employee Statistics, Revenue per Employee Trends for overall market, AMLN's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market, Revenue per Employee for AMLN's Competitors, Revenue per Employee for AMLN's Suppliers, Revenue per Employee for AMLN's Customers, Sales per Employee was $15.4 million, compared to $1.5 million a year ago. Amylin employees are dedicated in their ability to "think outside the box". Revenue Growth (TTM) Overall Greene served as CEO from 1987 to 1996.

Amylin Pharmaceuticals Inc's Revenue per Employee quarter by quarter results, averages and statistics, Financial Information - CSIMarket Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Revenue under the company's collaborative agreement with.

Amylin and Lilly are co-developing a drug to treat diabetes.

Ranking, Seq. Comment, Amylin Pharmaceuticals Inc's Revenues TTM, Companies with similar Revenue per Employee for 12 months ending Jun 30 2012, within Healthcare Sector. In 1987, Amylin Pharmaceuticals was co-founded by Howard E. Greene Jr., former CEO of San Diego biotech pioneer Hybridtech, to develop a treatment for diabetes from a synthetic analog of amylin. The company offers BYDUREON, a weekly diabetes treatment as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. Free Stock Market News Feeds, Competition Segments Revenue Growth Rates, Income from Continued Operations Annual Growth, Explore AMLN Customer Growth by Product and Service, Major Pharmaceutical Preparations Industry, Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics, Healthcare Sector Revenue Growth Statistics, Revenue Growth Trends for overall market, AMLN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market, Revenue Growth for Amylin Pharmaceuticals Inc's Suppliers, AMLN Revenue second quarter 2012 Y/Y Growth Comment, Amylin Pharmaceuticals Inc's second quarter 2012 Revenue, Amylin Pharmaceuticals Inc's second quarter 2011 Revenue, Revenue second quarter 2012 Y/Y Growth Company Ranking, Year on Year Revenue Growth Overall Net loss, excluding a restructuring charge of $3.4 million, was $40.8 million, or $0.28 per share. saw revenue surge tenfold in the third quarter, but increased expenses resulted in a wider per-share loss year over year, the company said. Free Stock Market News Feeds, Competition Segments Revenue Growth Rates, Income from Continued Operations Annual Growth, Compare AMLN Sales per Employee to its Competitors. Ranking, Cumulative Revenue growth The San Diego company, which makes drugs to treat metabolic disorders, registered a loss of $37.5 million, or 40 cents a share, compared to a loss of $31.3 million, or 39 cents a share, in 2002. Amylin Pharmaceuticals Inc's Revenue results by quarter and year, Amylin Pharmaceuticals Inc's Q/Q Revenue Growth, Amylin Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year, CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. In midday trading, shares of Amylin were up $1.18, or 4%, to $28.09.

What is Amylin Pharmaceuticals Inc selling? The Company reported total revenue of $164.4 million for the quarter ended June 30, 2010, which includes net product sales of $162.5 million.